Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image: Celea Therapeutics has dosed the first patient in the Phase 3 SURPASS-IPF trial testing deupirfenidone against pirfenidone for idiopathic pulmonary fibrosis.
Pharma & Biotech

Could deupirfenidone beat an approved IPF drug? Celea starts the Phase 3 test that will decide

Celea Therapeutics has begun an unusually ambitious Phase 3 program designed to prove that deupirfenidone is superior, rather than merely comparable, to the established antifibrotic pirfenidone. The approximately 1,100-patient trial could support a United States registration application if successful, but its 2029 readout leaves the company facing a long development period and an increasingly competitive

Read More
Representative image: Eplontersen’s Phase 3 CARDIO-TTRansform setback raises questions about AstraZeneca and Ionis Pharmaceuticals’ ATTR cardiomyopathy strategy.
Pharma & Biotech

Ionis Pharmaceuticals shares slide as eplontersen misses key heart disease endpoint

See why the CARDIO-TTRansform miss complicates eplontersen’s ATTR-CM path and tests gene silencing on top of stabilizer therapy.

Read More
Representative image: Alchemab Therapeutics’ £25 million funding supports AI-enabled antibody discovery, Resiliome expansion and new clinical programs.
Pharma & Biotech

Why British Business Bank just made its biggest life sciences bet on Alchemab Therapeutics

Alchemab Therapeutics secures £25 million to double its antibody data and advance two wholly owned programs toward clinical development.

Read More
Representative image: Apnimed, Inc. has filed for a Nasdaq IPO as investors weigh the commercial potential and FDA approval prospects of AD109, its once-nightly oral treatment for obstructive sleep apnea.
Pharma & Biotech

Apnimed files for Nasdaq IPO as oral sleep apnea drug AD109 nears FDA review

Apnimed, Inc. has filed for an initial public offering in the United States as it prepares for a potentially decisive regulatory year for AD109, its once-nightly oral treatment for obstructive sleep apnea. The Cambridge, Massachusetts-based pharmaceutical company plans to list on the Nasdaq Global Market under the ticker APMD, although the number of shares, proposed

Read More
Representative image: Huntington’s disease drug research faces another setback after Roche Holding AG discontinued tominersen and RG6496 following clinical efficacy and repeat-dosing concerns.
Pharma & Biotech

Roche ends two Huntington’s disease programmes after separate clinical setbacks

Roche Holding AG has discontinued development of tominersen and RG6496, removing two investigational huntingtin-lowering medicines from its neurology pipeline after separate setbacks emerged almost simultaneously. The Phase 2 GENERATION HD2 trial showed that tominersen lowered important biological markers but did not meaningfully slow clinical decline, while the Phase 1 POINT-HD study of RG6496 was halted

Read More
Biocon’s Yesafili aflibercept biosimilar is gaining new clinical support for retinal treatment and diabetic macular edema ahead of its planned U.S. launch. Representative image.
Pharma & Biotech

Biocon’s Yesafili has FDA approval, but these new switching results may decide whether eye specialists embrace it

Biocon’s new Yesafili studies add switching and subgroup evidence ahead of a planned U.S. launch in the competitive aflibercept market.

Read More
Confluence Genetics’ Cas-CLEAR CRISPR platform is designed to use cancer-linked RNA mutations as triggers for selective tumor cell destruction, opening a potential new precision oncology pathway. Representative image.
Pharma & Biotech

Could Confluence Genetics’ Cas-CLEAR platform open a new path for liver cancer therapy?

Confluence Genetics launches Cas-CLEAR, a Cas12a2 CRISPR platform designed to kill mutation-bearing cancer cells. Explore the evidence and risks.

Read More
Representative image: Delcath Systems has dosed the first patient in the Phase 2 DELUMA trial evaluating HEPZATO for liver-dominant HER2-negative metastatic breast cancer.
Pharma & Biotech

Can HEPZATO move beyond uveal melanoma? Delcath begins major metastatic breast cancer test

Delcath has dosed the first patient in the DELUMA Phase 2 trial, testing HEPZATO for liver-dominant HER2-negative metastatic breast cancer.

Read More
Auxilium Biotechnologies tests multi-product tissue manufacturing in microgravity
Pharma & Biotech

What Auxilium’s orbital kidney and liver bioprinting milestone means for regenerative medicine

Auxilium Biotechnologies bioprints kidney and liver tissues in orbit, advancing microgravity biofabrication while major clinical hurdles remain.

Read More
Sanofi’s Sarclisa Escena wins FDA approval for delivery through the CirCLIQ on-body injector, expanding wearable cancer treatment options for multiple myeloma. Representative image.
Pharma & Biotech

FDA approves Sanofi’s Sarclisa Escena with wearable injector for multiple myeloma

The United States Food and Drug Administration (FDA) has approved Sanofi’s Sarclisa Escena for subcutaneous administration through the CirCLIQ on-body injector, creating the first FDA-authorised anticancer treatment that can be delivered using a wearable injector. The regulator approved the fixed 1,400-milligram dose on July 9, 2026 for several multiple myeloma treatment combinations already supported by

Read More